New research into acute myeloid leukemia could change future treatment approaches.

Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute myeloid leukaemia (r/r AML) and myelodysplastic syndrome (MDS ...

Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

More than 30 percent of later-line patients responded to the drug in an existing Phase II trial, but some biomarker cohorts fared better.

Acute myeloid leukemia, often called AML, is one of the most aggressive forms of blood cancer. It develops in the bone marrow ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...

Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the ...

Researchers from the University of Toronto (Canada) have presented a new high-resolution gene expression atlas that shows the normal differentiation process of hematopoietic cells at the American ...

Socioeconomic factors, particularly education level, significantly impact access to allo-HCT for AML patients, with lower education reducing transplant likelihood by 30%. Reliance on government ...